{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:30Z","timestamp":1793047050072,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.idc.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:19:30Z","timestamp":1788293970000},"page":"741-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Staphylococcus aureus Skin and Soft Tissue Infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Nirusha A.","family":"Abeydeera-Keshmiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2026.07.003_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","article-title":"Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005\u20132010","volume":"15","author":"Miller","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2026.07.003_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/526773","article-title":"Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Miller","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2026.07.003_bib4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10096-025-05148-y","article-title":"The virulence toolkit of Staphylococcus aureus: a comprehensive review of toxin diversity, molecular mechanisms, and clinical implications","volume":"44","author":"Di Bella","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"27","key":"10.1016\/j.idc.2026.07.003_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5240","article-title":"Staphylococcus aureus LukMF\u2032 targets neutrophils to promote skin and soft tissue infection","volume":"11","author":"Boff","year":"2025","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib7","first-page":"202","article-title":"Ultrasound for the evaluation of skin and soft tissue infections","volume":"112","author":"O\u2019Rourke","year":"2015","journal-title":"Mo Med"},{"issue":"5","key":"10.1016\/j.idc.2026.07.003_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.annemergmed.2010.11.021","article-title":"A randomized controlled trial of incision and drainage versus ultrasonographically guided needle aspiration for skin abscesses and the effect of methicillin-resistant Staphylococcus aureus","volume":"57","author":"Gaspari","year":"2011","journal-title":"Ann Emerg Med"},{"issue":"26","key":"10.1016\/j.idc.2026.07.003_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1607033","article-title":"A placebo-controlled trial of antibiotics for smaller skin abscesses","volume":"376","author":"Daum","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.annemergmed.2017.07.483","article-title":"Subgroup analysis of antibiotic treatment for skin abscesses","volume":"71","author":"Talan","year":"2018","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.idc.2026.07.003_bib11","series-title":"StatPearls","article-title":"Incision and drainage","author":"Pastorino","year":"2026"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.idc.2020.10.003","article-title":"Staphylococcal skin and soft tissue infections","volume":"35","author":"Hatlen","year":"2021","journal-title":"Infect Dis Clin North Am"},{"issue":"12","key":"10.1016\/j.idc.2026.07.003_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","article-title":"Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections","volume":"372","author":"Miller","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.idc.2026.07.003_bib14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/cid\/ciw177","article-title":"A randomized trial of clindamycin versus trimethoprim-Sulfamethoxazole for uncomplicated wound infection","volume":"62","author":"Talan","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0974-2727.78558","article-title":"Inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples","volume":"3","author":"Prabhu","year":"2011","journal-title":"J Lab Physicians"},{"issue":"11","key":"10.1016\/j.idc.2026.07.003_bib16","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/JCM.01617-14","article-title":"Evaluation of the automated vitek 2 System for detection of various mechanisms of macrolide and lincosamide resistance in Staphylococcus aureus","volume":"52","author":"Filippin","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"19","key":"10.1016\/j.idc.2026.07.003_bib17","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1001\/jama.2016.15613","article-title":"Therapy for cellulitis","volume":"316","author":"Raff","year":"2016","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.idc.2026.07.003_bib18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2017.5653","article-title":"Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial","volume":"317","author":"Moran","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.idc.2026.07.003_bib19","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/cid\/cit122","article-title":"Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial","volume":"56","author":"Pallin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2026.07.003_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0190-9622(83)70020-4","article-title":"Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin","volume":"8","author":"Dillon","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.idc.2026.07.003_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","article-title":"Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections","volume":"24","author":"Bucko","year":"2002","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.idc.2026.07.003_bib22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/429628","article-title":"Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature","volume":"40","author":"Ruhe","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/femsre\/fux007","article-title":"Antibiotic resistance in staphylococcus aureus. Current status and future prospects","volume":"41","author":"Foster","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2026.07.003_bib25","first-page":"ofaf695","article-title":"P-815. A randomized trial of doxycycline vs. trimethoprim sulfamethoxazole (TMP-SMX) for uncomplicated skin and skin structure infections (SSSIs)","volume":"13","author":"Miller","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2026.07.003_bib26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2012.10845.x","article-title":"Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature","volume":"166","author":"Lebrun-Vignes","year":"2012","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.idc.2026.07.003_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/phar.2625","article-title":"Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: focus on doxycycline, minocycline, and omadacycline","volume":"41","author":"Bidell","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.idc.2026.07.003_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib29","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2026.07.003_bib30","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0924-8579(98)00074-0","article-title":"Fusidic acid in skin and soft tissue infections","volume":"12","author":"Spelman","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13756-021-00943-6","article-title":"The global prevalence of fusidic acid resistance in clinical isolates of staphylococcus aureus: a systematic review and meta-analysis","volume":"10","author":"Hajikhani","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib32","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","volume":"2016","author":"Yue","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib33","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2024.487","article-title":"Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis","volume":"5","author":"Greenfield","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"8","key":"10.1016\/j.idc.2026.07.003_bib34","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/ciad357","article-title":"Antibiotic myths for the infectious diseases clinician","volume":"77","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/sur.2021.329","article-title":"Impact of empiric linezolid for necrotizing soft tissue infections on duration of methicillin-resistant staphylococcus aureus-active therapy","volume":"23","author":"Lehman","year":"2022","journal-title":"Surg Infect"},{"issue":"4","key":"10.1016\/j.idc.2026.07.003_bib36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-021-01099-7","article-title":"Pharmacokinetics and pharmacodynamics of tedizolid","volume":"61","author":"Iqbal","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.idc.2026.07.003_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/20009666.2019.1651482","article-title":"Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium","volume":"9","author":"Tirupathi","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"2","key":"10.1016\/j.idc.2026.07.003_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0974-2727.119862","article-title":"Fluoroquinolone therapy in Staphylococcus aureus infections: where do we stand?","volume":"5","author":"Gade","year":"2013","journal-title":"J Lab Physicians"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2026.07.003_bib40","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2026.07.003_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106946","article-title":"Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis","volume":"62","author":"Zhang","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2026.07.003_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","article-title":"Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features","volume":"21","author":"Cong","year":"2020","journal-title":"J Adv Res"},{"issue":"11","key":"10.1016\/j.idc.2026.07.003_bib43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/TCRM.S1843","article-title":"A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)","volume":"4","author":"Dunbar","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.idc.2026.07.003_bib45","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2147\/TCRM.S115175","article-title":"Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis","volume":"12","author":"Liu","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of daptomycin, tigecycline, quinupristin\/dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2026.07.003_bib47","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1201-9712(07)60002-2","article-title":"Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections","volume":"11","author":"Grolman","year":"2007","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2026.07.003_bib48","first-page":"e01715","article-title":"In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2026.07.003_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01816-17","article-title":"Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin","volume":"62","author":"Eljaaly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2026.07.003_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2026.07.003_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"10.1016\/j.idc.2026.07.003_bib52","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2147\/IDR.S455515","article-title":"Real-world use and treatment outcomes of ceftaroline fosamil in patients with complicated skin and soft tissue infection: a multinational retrospective study","volume":"17","author":"Ferry","year":"2024","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10.1016\/j.idc.2026.07.003_bib53","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2026.07.003_bib54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1507476","article-title":"Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess","volume":"374","author":"Talan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2026.07.003_bib55","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2026.07.003_bib56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","article-title":"Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial","volume":"26","author":"Cranendonk","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.idc.2026.07.003_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac197","article-title":"Early switch from intravenous to oral antibiotics in skin and soft tissue infections: an algorithm-based prospective multicenter pilot trial","volume":"9","author":"Dellsperger","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2026.07.003_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001825","article-title":"An unsupported preference for intravenous antibiotics","volume":"12","author":"Li","year":"2015","journal-title":"PLoS Med"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552026000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552026000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:06:17Z","timestamp":1793045177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552026000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0891552026000644"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2026.07.003","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Staphylococcus aureus Skin and Soft Tissue Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}